1313591-69-3

Basic information

• Product Name: 2-(4-(trifluoromethyl)phenyl)-1H-benzimidazole-5-carboxylic acid
• Synonyms: 2-(4-(trifluoromethyl)phenyl)-1H-benzimidazole-5-carboxylic acid
• CAS NO: 1313591-69-3
• Molecular Weight: 306.244
• Mol File: 1313591-69-3.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2-(4-(trifluoromethyl)phenyl)-1H-benzimidazole-5-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-(trifluoromethyl)phenyl)-1H-benzimidazole-5-carboxylic acid(1313591-69-3)
• EPA Substance Registry System: 2-(4-(trifluoromethyl)phenyl)-1H-benzimidazole-5-carboxylic acid(1313591-69-3)

Safety Data

• Hazardous Substances Data: 1313591-69-3(Hazardous Substances Data)

Upstream product

• 152782-75-7 sodium hydroxy(4-(trifluoromethyl)phenyl)methanesulfonate 
• 619-05-6 3,4-diaminobenzoic acid 
• 455-19-6 4-Trifluoromethylbenzaldehyde 

Downstream Products

• 1259500-87-2 4''-O-(2-(4-trifluormethylphenyl)-1H-benzimidazole-5-carbonyl)hydrazinecarbonylclarithromycin 
• 760120-67-0 C₁₅H₈ClF₃N₂O 

Relevant articles and documents

Novel clarithromycin analogs with C-4′′ 2-arylbenzimidazolyl bishydrazide side chain: Synthesis and antibacterial evaluation

A series of novel 4′′-O-2-arylbenzimidazolyl derivatives of clarithromycin were synthesized and evaluated. These 4′′-O-2- arylbenzimidazolyl derivatives demonstrated excellent activity against erythromycin-susceptible strains and showed remarkably improved activity against erythromycin-resistant strains compared with the references. In particular, compound 7c, which possesses the terminal 2-(2-methoxyphenyl)benzimidazolyl group on the C-4′′ bishydrazide side chain, not only presented the most potent activity against erythromycin-susceptible Streptococcus pneumoniae ATCC49619 and Staphylococcus aureus ATCC25923, exhibiting 4-fold and 4-fold higher efficacy than the parent clarithromycin, but also displayed the highest activity against erythromycin-resistant Streptococcus pneumoniae expressing the mef gene and the erm gene, which was 133-fold and 32-fold better than clarithromycin or azithromycin, respectively.